Interleukin-17 aggravates right ventricular remodeling via activating STAT3 under both normoxia and hypoxia

Huang Jing^{1#}, Wei Zhang^{2#}, Cai-lian Zhang³, Lei Wang^{4*}

- 1. Department of Rheumatism and Immunology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China
- 2. Department of Emergency Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China
- 3. Department of Pulmonary and Critical Care Medicine, Yanan University Affiliated Hospital, Yanan 716000, P.R. China
- 4. Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, P.R. China

* Corresponding author

Address for reprint requests and other correspondence:

Dr. Lei Wang

No. 157 Xiwu Road, Xin Cheng District, Xi'an 710004, P.R. China

Tel: 029-87679973

Email: w1860806wb@163.com

Running title: IL-17 and right ventricular remodeling




Figure 3C

A: WT 1

B: IL17 KO 1

C: IL17 KO 2

D: WT 2

E: WT 3

F: IL17 KO 3

G: WT 4

H: IL17 KO 4

I: WT 5

J: IL17 KO 5

K: WT 6

L: IL17 KO 6




Figure S1 IL-17 expression in cardiomyocytes after hypoxia exposure.




Figure S2 Expression of p-STAT3 in cardiomyocytes when treated with hypoxia exposure or/and IL-17.





Figure S3 Expression of Bax after treated with IL-17 or STAT3 inhibitor under normoxia and hypoxia.



F5Ba

Normoxia

A: Control

B: IL-17

C: IL-17+STAT 3 inhibitor

Hypoxia

D: Control

E: IL-17

F: IL-17+STAT 3 inhibitor

Figure S4 Expression of Bcl-2 after treated with IL-17 or STAT3 inhibitor under normoxia and hypoxia.






Figure S5 Expression of Caspase3 after treated with IL-17 or STAT3 inhibitor under normoxia and hypoxia.

Flowchart of in vivo experiments

Experiment of Figure 1



Experiment of Figure 2



Flowchart of in vivo experiments

Experiment of Figure 3

